多西他赛聚合物胶束的制备、表征及其对前列腺癌细胞LNCap-C4-2B的抑制作用

目的制备多西他赛-聚乙二醇-聚己内酯嵌段共聚物(PEG-PCL-DTX,DTX-PMs)胶束,研究多西他赛-聚乙二醇-聚己内酯嵌段共聚物的载药量、包封率及体外释放,考察对前列腺癌细胞株LNCaP-C4-2B的抑制增长效应。方法采用透射电镜观察纳米胶束的形态,采用激光粒度仪、高效液相色谱法对胶束的粒径,电位,载药量,包封率、体外释放进行研究;采用MTT法检测多西他赛-聚乙二醇-聚己内酯嵌段共聚物对前列腺癌细胞LNCap-C4-2B的抑制作用,并与市售的多西他赛(多帕菲)进行比较。结果多西他赛-聚乙二醇-聚己内酯嵌段共聚物胶束的载药量和包封率分别为(8.72±0.24)%和(98.1±1.6)%,平均粒径为(25.19±2.36)nm,电位为(0.64±0.15)mV;体外释放具有一定缓释效应;MTT试验结果显示,多西他赛-聚乙二醇-聚己内酯嵌段共聚物能够很好地抑制LNCaP-C4-2B细胞的增长。结论多西他赛能够被多包载制备成胶束,其粒径小,稳定性好,可显著提高多西他赛在水相中的浓度,在体外具有良好的缓释效果和肿瘤细胞抑制作用。

Development,Characterization and in Vitro Evaluation of Docetaxel-Loaded Polymeric Micelles

OBJECTIVE To employ PEG-PCL diblock copolymers to prepare DTX-loaded polymeric micelles (PEG-PCL-DTX micelles, DTX-PMs) which addressed the issue of DTX′s drug loading capacity, encapsulation efficiency and in vitro release. We also studied its effectiveness for the cytotoxicity on prostate cancer.METHODS The polymeric micelles were screened by its shape using transmission electron microscope and were also characterized in terms of particle size, Zeta potential, drug loading efficiency, in vitro release and cytotoxicity by using laser particle size analyzer and HPLC. Cytotoxicity against LNCap-C4-2B prostate cancer cells of the DTX-PMs and commercial product of Duopafei^ were evaluated by MTT assay. RESULTS The average particle size and Zeta potential of DTX-PMs were found to be 25.1 nm and 0.64 mV. The micelles′ drug loading and encapsulation efficiency were 8.72% and 98.1%, respectively. Cytotoxicity assay showed that DTX-PMs exerted significant anti-proliferation activity on LNCap-C4-2B prostate cancer cells. CONCLUSION Slightly soluable DTX successfully formulated into the PEG-PCL micells, exhibiting small partical size and good stability. Delayed release in vitro and maintained quite a constant concentration in plasma for a long period, which was favorable for its clinic application. In conclusion, DTX-PMs developed here sufficiently solubilized DTX and increase the concentration of DTX in aqueous phase, offering a sustained in vitro release and effective cytotoxicity on LNCap-C4-2B prostate cancer.